argenx NV ADR (ARGX)

Argenx (ISIN NL0010832176) stock is trading near its 52-week high after reporting strong Q2 2026 results. The company achieved double-digit revenue growth, a profit margin exceeding 31%, and earnings per share that surpassed analyst expectations. This performance, driven by demand for its autoimmune therapies, has reinforced investor confidence despite a slight intraday dip.

Argenx SE stock is trading near its 52-week high after reporting strong Q2 fiscal 2026 earnings, including $1.51 billion in revenue and $472 million in earnings, with a 31.16% profit margin. Despite a downgrade to "Hold" due to valuation concerns, analysts maintain a "Moderate Buy" consensus with an average price target above current trading levels. The company also announced positive Phase 3 trial results for efgartigimod in autoimmune myositis and a $2.2 billion acquisition of Forte Biosciences to expand its immunology platform.

Argenx stock is trading above €780 in Europe and $1,039 on Nasdaq, reflecting a strong market capitalization of €48.6 billion and $65.03 billion respectively. The company's high valuation is supported by substantial revenue growth, a leading antibody-based therapy, and a promising pipeline, with analysts projecting further upside despite recent gains. Key financial metrics include an EBITDA of $2.03 billion, a P/E ratio of 32.97, and a low debt-to-equity ratio of 0.19.

argenx SE's VYVGART Hytrulo showed positive results in its Phase 3 ALKIVIA trial for immune-mediated necrotizing myopathy (IMNM), a significant win as there's no approved treatment for IMNM. However, the trial's dermatomyositis subgroup, which represents a larger patient population, did not achieve statistical significance, raising questions about the drug's full market potential and regulatory path. Despite this, the established drug's expansion into IMNM is seen as a credible opportunity.

Argenx stock is trading above $1,030, supported by rising long-term earnings forecasts and a solid year-to-date gain, reflecting confidence in its autoimmune pipeline. The company reported strong Q3 earnings, beating consensus estimates for both EPS and revenue, and analysts project significant EPS growth through 2030. A recent Phase 3 win for VYVGART Hytrulo in autoimmune myositis further strengthens the company's growth narrative and potential market expansion.